ArticlePloS one2015
Baseline C-Reactive Protein Levels and Life Prognosis in Parkinson Disease.
Article in PloS one, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT05469997 (Ketogenic Diet Interventions in Parkinson's Disease), which is not on this map. Cited by 32 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Ketogenic Diet Interventions in Parkinson's Disease: Safeguarding the Gut Microbiome
Who cites it
32 citing papers in PubMed, 58 citations in OpenAlex.
- Serum C-Reactive Protein as a Prognostic Biomarker in Amyotrophic Lateral Sclerosis.JAMA neurology · 2017Trial
- Frailty in Parkinson's disease: time to integrate it into treatment decision-making?Journal of neural transmission (Vienna, Austria : 1996) · 2026Review
- The brain and heart-axis in neurodegeneration and cardiovascular disease.Journal of neural transmission (Vienna, Austria : 1996) · 2026Review
- Tracing neuroinflammation in neurodegeneration: insights from a scoping review on biofluid biomarkers.Brain communications · 2026Review
- Aerobic exercise-induced changes in fluid biomarkers in Parkinson's disease.NPJ Parkinson's disease · 2025Review
- C-reactive protein: the nexus between inflammation and protein misfolding diseases.Frontiers in immunology · 2025Review
- Investigating the Genetic Association of 40 Biochemical Indicators with Parkinson's Disease.Journal of molecular neuroscience : MN · 2024Article
- The Contribution of Type 2 Diabetes to Parkinson's Disease Aetiology.International journal of molecular sciences · 2024Review
- How should we be using biomarkers in trials of disease modification in Parkinson's disease?Brain : a journal of neurology · 2023Article
- C-Reactive Protein: Pathophysiology, Diagnosis, False Test Results and a Novel Diagnostic Algorithm for Clinicians.Diseases (Basel, Switzerland) · 2023Review
- Parkinson's disease and cardiovascular involvement: Edifying insights (Review).Biomedical reports · 2023Review
- Article
- C-reactive protein as the biomarker of choice to monitor the effects of exercise on inflammation in Parkinson's disease.Frontiers in immunology · 2023Article
- Laboratory prognostic factors for the long-term survival of multiple system atrophy.NPJ Parkinson's disease · 2022Article
- Role of High-Sensitivity C-reactive Protein (Hs-CRP) in Non-communicable Diseases: A Review.Cureus · 2022Review
- Blood-based biomarker in Parkinson's disease: potential for future applications in clinical research and practice.Journal of neural transmission (Vienna, Austria : 1996) · 2022Review
- Association between levels of high-sensitivity C-reactive protein in plasma and freezing of gait in Parkinson's disease.Aging clinical and experimental research · 2022Article
- Blood and Cerebrospinal Fluid Biomarkers of Inflammation in Parkinson's Disease.Journal of Parkinson's disease · 2022Review
- Soluble CD163 Changes Indicate Monocyte Association With Cognitive Deficits in Parkinson's Disease.Movement disorders : official journal of the Movement Disorder Society · 2021Article
- Periphery and brain, innate and adaptive immunity in Parkinson's disease.Acta neuropathologica · 2021Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundC-reactive protein (CRP) is a biomarker of inflammation, and high levels of CRP correlate with vascular death. Chronic inflammation is considered to be involved in neurodegeneration, although there is no evidence linking it with the process of neurodegenerative diseases.
objectiveTo determine the role of baseline CRP levels in the prognosis of patients with Parkinson disease (PD).
methodsA cohort of 313 patients with a mean age of 69.1 and mean PD duration of 7.9 years was retrospectively followed for a mean observation time of 1,753 days. CRP was measured when patients were not diagnosed with any infections, and levels were repetitively measured to investigate a tendency of "regression to mean." The primary outcome measure was a survival time from study enrollment to death.
resultsDuring the observation period 56 patients died. Baseline CRP was log-linearly associated with a risk of death in PD. Mean survival time was 3,149 (95% confidence interval; 3,009-3,289) days in patients with CRP ≤ 0.8mg/L (lower two thirds) and 2,620 (2,343-2,897) days in those with CRP > 0.8 mg/L (top third, p < 0.001, log-rank test). The adjusted hazard ratio (HR) per two-fold higher CRP concentration for all deaths was 1.29 (1.10-1.52), and after excluding PD-unrelated deaths, such as cancer or stroke, HR was 1.23 (1.01-1.49) (adjusted for age, sex, PD duration, modified Hohen-Yahr stages, MMSE scores, and serum albumin).
conclusionsBaseline CRP concentrations were associated with the risk of death and predicted life prognosis of patients with PD. The associations were independent from PD duration, PD severity, cognitive function, ages, and nutritional conditions, suggesting the possibility that subclinical chronic inflammation is associated with a neurodegenerative process in PD.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.